tezepelumab
Selected indexed studies
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. (N Engl J Med, 2021) [PMID:33979488]
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. (N Engl J Med, 2025) [PMID:40106374]
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (J Allergy Clin Immunol, 2023) [PMID:36538979]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2023) pubmed
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. (2021) pubmed
- Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. (2024) pubmed
- Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. (2023) pubmed
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. (2025) pubmed
- Tezepelumab. (2012) pubmed
- Tezepelumab. (2006) pubmed
- Tezepelumab in patients with allergic and eosinophilic asthma. (2024) pubmed
- Tezepelumab in Adults with Uncontrolled Asthma. (2017) pubmed
- Tezepelumab: First Approval. (2022) pubmed